Sunday, December 01, 2019 1:31:42 PM
Hidalgo is a paid consultant. Eurofins, and Medscape are paid contractors. All are paid for appearance. Kenny doesn't pay a Eurofins or a Hidalgo out of his own pocket. Again again again again again the setup is Kenny sells discounted blocks of shares to a 3rd party for cash up front. Kenny's job is to ensure with his PR pumps the 3rd party can make a nice profit, and comes back for more shares. If retail gets excited over the name of Hidalgo, and it helps Kenny sell blocks of shares, he's more than happy to throw $50K+ to a Hidalgo. And Hidalgo is happy to accept it.
Only one problem, AN didn't build anything "huge". It's sort of difficult to build a "huge" biotech manufacturing facility with $2-3M. Might even say it's downright impossible.
First it was the Thai gov, that footed the bill to build the buildings, and assist in providing a clean room infrastructure (e.g. appropriate air flow from the bldg) for any entity that wanted to lease some rooms. In AN's case from all of the wonderful pictures Kenny provided, they apparently have two small room areas for the manufacturing, a small lab outside of the two small rooms. Along with an outer area for a conference room, and entrance room. Neither being able to create a clean room makes anything state of the art.
You do for appearances.
No, not green tea. Instead this scam has a weed (THC) scam angle. Where anything associated with weed is popular in the OTC Market.
No it's an unreal technology. Where the dog study proved the higher the tumor load, the less a given cancer is likely to respond to a given treatment. Hardly scientific news. Neither could Simpson and Hidalgo care about a faulty canine mammary cancer study.
They get far less than Kenny, and the BODs get each quarter.
Microcrap biotech scams dilute with billions of shares. Legit small caps typically are in the range of under 100M, with 1 or more CTs, already in progress, and the cash to fund them fur 2 yrs+. A real biotech sitting on the Nasdaq doesn't dilute itself for 1.3B+ shares, and produce zero in the way of results for 8 yrs. The big kids do not suffer such tactics.
The SEC does not investigate or pass judgements on claims about science in a scam. They are only interested in investigating whether SEC regulations have been violated or not. PMCB does have problems in how they apparently didn't adhere to the bylaws. They better be careful in the coming Dec 10Q in one area.
Just as they were when Kenny promised a CT for Q3 2015, and EOY 2016. Which would've been beyond a mere mythical IND.
They have announced nothing that suggests a mythical CT will be "very successful" in a 2nd line setting.
3rd parties in the past have done exactly that and have made profit. PMCB has not. And with the Shelf currently frozen, there is no money coming in for Kenny's salary.
A legit biotech doesn't make money from a CT. A CT costs money to stage. However, Kenny might profit on nonsense over a filing - assuming he gets the workaround in place for the frozen Shelf.
CTs don't work that way. Assuming PMCB can afford a mythical CT, which they can't currently, the first problem will be patient enrollment. Even with legit treatments for pancreatic cancer, showing dramatic results in previous FDA sanctioned CTs, enrollment can be slow. Past FDA sanctioned CTs don't exist for PMCB. No doubt Kenny would pump out of the kazoo any tumor shrinkage in the only patient to be recruited "weeks later". Which is meaningless. At last check the proposed endpt was PFS. Which would be followed for close to a year only if it worked. Expected based on the difficulties of treating 2nd line patients, plus the history of the use of Ifosfamide, for such purposes, the Kenny Wonder Treatment will fail, having reached median PFS, at 3 months.
There is nothing "Surgically precise" about Chemo. Provide a link which gives the amount of Ifosfamide converted in the human body by locally implanted CIABs - there is no such link. Provide a link that shows the presence of CIABs make any difference when Metronomic Ifosfamide is administered - there is none. Therefore, any claims made by Kenny about CIABs are unproven. There will be side effects due to the Ifosfamide. These include neutropenia, as a result of bone marrow suppression, bladder inflammation, unless Mensa is given (as Lohr did), and neurological toxicity.
No we do not. In fact, a more developed thicker stromal layer in 2nd line patients (if any patients enroll) is extremely difficult to treat. Past results using Ifosfamide at 1.2 gms/m2 gave a 3 month PFS in 2nd line, along with neurological effects. The lower 1 gm/m2 is likely to have the same or less effect.
Finally a point of agreement. Yes Gunzburg&Salmons helped setup the PMCB scam for the purpose of infusing cash into their company AN. It was all legal in its setup. Then they brought in Kenny to PR pump the stock. Since Kenny had prior P&D scam experience.
Then poor Kenny, because it will not work. However, maybe one of his PR pumps will work in the future, so he can dump? As a 1933 filer, he can dump at any time without filing a Form 4. In fact he gets 300K of stock to dump every month. A continuing resupply from year to year.
First it's highly unlikely the IND submission will not be announced. Again...if Kenny ever submits the mythical IND asking for a Phase 2b it will be rejected. If he submits the mythical IND as a Phase 1, it has a 40:60 chance of getting approved by the FDA. Which is better than zero percent chance. Then maybe Kenny can PR pump a short spike of a few pennies, before it goes back down. How fast, it goes up/down depends on how many more shares are being held by 3rd parties waiting to be dumped. Potential for retail traders to benefit - assuming the huge dump doesn't bury traders. One thing for sure, is recent paid promos, haven't resulted in 1.3B+ shares being bid up, and supported by retail. If Kenny wants to follow through on his charade of the mythical CT, he'll need to dilute hundreds of millions of shares more. All discounted to 3rd parties of course. Then the question becomes: If retail can't current bid up, and support the current O/S of 1.3B+, how will they do so with 2B+ in the future? Dilution in Microcrap stocks is never a problem, until after it happens.
The Jewel of the Mind is Colored with the Hue of what it Imagines
Recent PMCB News
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 08/13/2024 08:37:40 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 07/29/2024 08:05:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 08:59:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 08:58:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 08:58:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 08:58:35 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/30/2024 08:05:04 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 05/30/2024 08:05:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/23/2024 08:40:20 PM
- PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease • Business Wire • 05/21/2024 01:00:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 08:38:38 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/06/2024 02:56:28 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 12/15/2023 10:25:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/24/2023 09:00:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:02:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:02:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:01:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:01:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:01:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:00:10 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 11/22/2023 09:00:15 PM
- PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women’s Health Innovator Femasys, Inc. • Business Wire • 11/15/2023 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 10:25:09 PM
- PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology • Business Wire • 10/31/2023 01:15:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM